Valneva SE (VALN)
7.13
-0.11
(-1.52%)
USD |
NASDAQ |
May 09, 16:00
7.13
0.00 (0.00%)
After-Hours: 18:04
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 496.08M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -40.85% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 2.969 |
Price to Book Value | 3.499 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 1.379 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales. |
URL | https://www.valneva.com |
Investor Relations URL | https://valneva.com/investors/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Aug. 13, 2024 |
Last Earnings Release | May. 07, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales. |
URL | https://www.valneva.com |
Investor Relations URL | https://valneva.com/investors/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Aug. 13, 2024 |
Last Earnings Release | May. 07, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |